Nestlé/Galderma Expands U.S. Dermal-Filler Stake As Valeant Raises Bid For Allergan
This article was originally published in The Gray Sheet
Executive Summary
Swiss dermatology firm Galderma, soon to be a Nestlé subsidiary, will gain access to the Sculptra dermal filler device and a North American sales presence for four other medical aesthetics products in a $1.4 billion sell-off by Valeant intended to strengthen its position to buy Allergan.